SM-164

Item no.	HY-15989-100mg
Manufacturer	MedChem Express
CASRN	957135-43-2
Amount	100 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 mg 50 mg 5 mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Breast Cancer
Type	Inhibitors
Specific against	other
Purity	99.49
Citations	[1]Sun H, et al. Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. J Am Chem Soc. 2007 Dec 12;129(49):15279-94.\|[2]Lu J, et al. SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. Cancer Res. 2008 Nov 15;68(22):9384-93. Biomater Adv. 2025 Jan 13:170:214185.\|Biomed Res Int. 2019 Apr 7;2019:2121357.\|Bioorg Chem. 2022: 106339.\|Bioorg Chem. 2023 Jun 1;137:106647.\|Bioorg Chem. 2024 Jan, 142, 106964.\|Bioorg Med Chem. 2023 Aug 15, 91, 117385.\|Bioorg Med Chem. 2024 Feb 15:100:117611.\|Bioorg Med Chem. 2024 Mar 1:102:117659.\|bioRxiv. 2023 Apr 25.\|bioRxiv. 2023 Aug 24.\|Cancer Cell. 2025 Mar 5:S1535-6108(25)00069-8.\|Cell Death Dis. 2024 Oct 18;15(10):759.\|Cell Death Dis. 2018 Nov 15;9(12):1140. \|Cell Death Discov. 2024 Mar 23;10(1):152.\|Cell Res. 2023 Sep 19.\|Curr Protoc. 2021 Jun;1(6):e156.\|Eur J Med Chem. 2021 Apr 27;220:113484.\|Eur J Med Chem. 2022 Jun 5;236:114345.\|Eur J Med Chem. 2024 Mar 9, 116304.\|Georg Thieme Verlag KG\|Int J Biol Macromol. 2023 Jun 13;125373.\|J Cell Mol Med. 2023 Aug 29.\|J Med Chem. 2022 Oct 26.\|J Med Chem. 2023 Feb 23;66(4):3073-3087.\|J Med Chem. 2023 Mar 12.\|Mater Sci Eng C Mater Biol Appl. 29 December 2021, 112615.\|Mol Neurobiol. 2023 Jan 5.\|Nature. 2024 Apr;628(8009):835-843.\|Patent. US20230192662A1.\|Patent. US20240217963A1.\|Patent. US20240294508A1.\|PLoS Pathog. 2024 Aug 30;20(8):e1012387.\|Proc Natl Acad Sci U S A. 2022 Sep 6;119(36):e2117396119.\|Research Square Print. 2022 May.\|Rheumatology. 2022 Oct 29;keac621.\|Sci Immunol. 2024 Jul 12;9(97):eadn0178.\|Signal Transduct Target Ther. 2020 Oct 9;5(1):235.\|J Ethnopharmacol. 2023 Nov 1:117373.
Smiles	C[C@H](NC)C(N[C@H]1CCCC[C@](CC[C@H]2C(N[C@@H](C3=CC=CC=C3)C4=CN(CCCCC5=CC=C(CCCCN6N=NC([C@@H](NC([C@@H]7CC[C@@](CCCC[C@@H]8NC([C@@H](NC)C)=O)([H])N7C8=O)=O)C9=CC=CC=C9)=C6)C=C5)N=N4)=O)([H])N2C1=O)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	957135-43-2
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Apoptosis; IAP
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	1121.42
Product Description	SM-164 is a cell-permeable Smac mimetic compound. SM-164 binds to XIAP protein containing both the BIR2 and BIR3 domains with an IC50 value of 1.39 nM and functions as an extremely potent antagonist of XIAP.
Manufacturer - Research Area	Cancer
Solubility	DMSO: 25 mg/mL (ultrasonic)
Manufacturer - Pathway	Apoptosis
Isoform	cIAP; cIAP-1; cIAP-2
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-15989-100mg-safety-datasheet.pdf